Growth Metrics

Eli Lilly (LLY) Cash from Investing Activities (2016 - 2026)

Eli Lilly filings provide 18 years of Cash from Investing Activities readings, the most recent being -$3.9 billion for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 16.79% to -$3.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$11.5 billion, a 0.5% decrease, with the full-year FY2025 number at -$11.0 billion, down 17.95% from a year prior.
  • Cash from Investing Activities hit -$3.9 billion in Q1 2026 for Eli Lilly, down from -$2.8 billion in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$459.1 million in Q2 2023 to a low of -$4.0 billion in Q3 2024.
  • Median Cash from Investing Activities over the past 5 years was -$1.9 billion (2024), compared with a mean of -$2.1 billion.
  • Biggest five-year swings in Cash from Investing Activities: soared 44.45% in 2023 and later crashed 378.92% in 2024.
  • Eli Lilly's Cash from Investing Activities stood at -$943.5 million in 2022, then plummeted by 209.97% to -$2.9 billion in 2023, then skyrocketed by 34.32% to -$1.9 billion in 2024, then plummeted by 45.87% to -$2.8 billion in 2025, then crashed by 39.75% to -$3.9 billion in 2026.
  • The last three reported values for Cash from Investing Activities were -$3.9 billion (Q1 2026), -$2.8 billion (Q4 2025), and -$3.0 billion (Q3 2025) per Business Quant data.